MEDPLUS Q4 FY26 Results Analysis: PAT Jumps 24.6%, Diagnostics Turnaround Lifts Performance
MEDPLUS's Q4 FY26 numbers came in strong, with revenue of Rs. 1,864.39 Cr (+23.50% YoY) and PAT growth of +24.60% YoY. Here's a quick read of what worked, what to watch, and what management said.
| Results date | May 20, 2026 |
|---|---|
| Quarter | Q4 FY 2025-2026 |
| Revenue (Q4) | Rs. 1,864.39 Cr (+23.50% YoY) |
| PAT (Q4) | Rs. 63.97 Cr (+24.60% YoY) |
| EBITDA margin | 9.07% (+56 bps YoY) |
| EPS (Q4) | Rs. 5.33 (+23.40% YoY) |
| Market cap | Rs. 11,340.98 Cr |
| CMP | Rs. 950.20 |
Quarter Snapshot
MEDPLUS delivered strong Q4 with 23.5% revenue growth and 24.6% PAT growth, though FY26 revenue of 12.3% missed the 15% guidance. The diagnostics turnaround (Rs.17.4 Cr profit vs Rs.109.8 Cr loss) and strong cash conversion (2.26x PAT) are key positives. Margin expansion of 56 bps and 10.5% SSG demonstrate execution quality, though revenue guidance miss and regulatory risks warrant monitoring.
Key Investment Insights
Key Positives
- Revenue grew 23.5% YoY in Q4 to Rs.1,864.4 Cr
- PAT grew 24.6% YoY in Q4 to Rs.64 Cr, and 46.1% for FY26 to Rs.219.6 Cr
- EBITDA margin expanded 56 bps YoY to 9.07%
- Diagnostics segment turned profitable at Rs.17.4 Cr FY26 vs loss of Rs.109.8 Cr FY25
- Operating cash flow strong at Rs.495.6 Cr, 2.26x PAT
- ROE improved to 11.1% from 8.5%
- Private label constituted 22.2% of revenue in Q3
Risk Factors
- Revenue growth of 12.3% for FY26 missed ~15% guidance by 270 bps
- Drug license suspensions continue with ~Rs.31 lakhs revenue impact
- Working capital deteriorated with Rs.98.5 Cr cash tied up
- Finance costs grew 24.7% YoY driven by lease liability expansion
Ask about this
Ask Cofacto a question about this result. Answers cite filings and company data.
Related
Disclaimer: This results analysis is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.